Brief: FDA Accepts Organogenesis' Biologics License Application For Renu
06/07/2026 21:24
BRIEF-FDA Accepts Organogenesis' Biologics License Application For Renu July 6 (Reuters) - Organogenesis Holdings Inc ORGO.O:
ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR RENU® FOR THE MANAGEMENT OF SYMPTOMATIC KNEE OSTEOARTHRITIS
FDA SETS PDUFA TARGET ACTION DATE OF APRIL 24, 2027 FOR RENU BLA
Source text: ID:nGNX5ZY7Nb
Further company coverage: ORGO.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers